hims hers stock - Search News

Hims is officially phasing out its copycat weight-loss drugs

Hosted on MSN · 28m

Hims & Hers will stop selling some weight loss drugs — and the stock plummets 27%

Hims & Hers (HIMS) stock took a steep dive, dropping more than 27%Tuesday morning — even after the millennial-focused telehealth company reported soaring sales for 2024 just the night before.

YAHOO!Finance · 1h

Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.

Wall Street Journal · 2h

Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

Hims, Hers

Barron's on MSN · 4h

Hims & Hers Stock Tumbles Despite Beating Expectations

Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering better-than-expected revenue forecasts for the first quarter and 2025.For the full year 2025,

HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer in shortage.

MarketWatch · 19h

Hims & Hers Shares Sink Despite Upbeat Earnings, Outlook

Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth quarter.

15h

Hims & Hers offers upbeat forecast, but stock slides after hours

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

2h

Hims & Hers Health Stock Is Plunging Tuesday: What's Going On?

Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to ...

5h

Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...

4don MSN

Why Hims & Hers Stock Dropped Today

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

1hon MSN

These Stocks Are Moving the Most Today: Super Micro, Nvidia, Home Depot, Palantir, Hims & Hers, Eli Lilly, MicroStrategy, and More

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...

14h

Hims & Hers: Post Earnings Drop Is Very Welcomed

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results